Company profile
Bristol-Myers Squibb Company operates globally as a biopharmaceutical powerhouse, engaging in the research, development, licensing, manufacturing, and marketing of innovative health solutions. Its extensive product pipeline addresses critical conditions across various therapeutic areas, including hematology, oncology, cardiovascular health, immunology, fibrotic diseases, neuroscience, and COVID-19. Key offerings from the company include Revlimid, an oral immunomodulatory drug for treating multiple myeloma, and Eliquis, an oral inhibitor prescribed for reducing stroke risk in non-valvular atrial fibrillation and for managing deep vein thrombosis/pulmonary embolism. The anti-cancer therapy Opdivo is also part of its portfolio, alongside Pomalyst/Imnovid for multiple myeloma, and Orencia, used for adult patients with active rheumatoid arthritis and psoriatic arthritis. Other notable treatments comprise Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy product. Furthermore, the company provides Reblozyl for anemia in adult beta thalassemia patients, and Empliciti for multiple myeloma. More recent additions include Zeposia, targeting relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor for adult myelofibrosis; and Onureg, prescribed for adult acute myeloid leukemia. Bristol-Myers Squibb distributes its products through a wide network encompassing wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The firm, established in 1887 and formerly known as Bristol-Myers Company, is headquartered in New York, New York.
- CEO
- Christopher S. Boerner
- Employees
- 32,500
- IPO date
- 14 May 1999
- ISIN
- US1101221083
